Eli Lilly and Company
Tracked across 54 events · 1012 articles · First seen Jan 07, 2025 · Last active Jun 12, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
Eli Lilly and Company has announced agreements to acquire three vaccine developers: Ćurevo, LimmaTech Biologics, and Vaccine Company, for a combined total of up to $3.83 billion. This strategic move marks Eli Lilly and Company's…
Impact: Eli Lilly and Company is acquiring three vaccine developers, marking its re-entry into the infectious disease space and expanding its R&D efforts. This move is expected to support its growth beyond its core diabetes and obesity portfolio.
May 26, 2026 · 7 articles
Business
Hanmi Pharm has entered into a licensing agreement with Eli Lilly and Company for its biologic drug candidate, sonefpeglutide (GLP-2 analog). Under the agreement, Eli Lilly and Company gains exclusive worldwide rights, excluding South Korea,…
Impact: Eli Lilly and Company obtained exclusive worldwide rights (excluding Korea) to develop, manufacture, and commercialize sonefpeglutide, expanding its pipeline in areas like short bowel syndrome and other indications, potentially leading to new revenue streams.
Jun 01, 2026 · 11 articles
Regulatory
Impact: Eli Lilly and Company agreed to lower prices for its obesity drug Zepbound and will sell a starter dose for $299 a month, with additional doses up to $449, representing $50 reductions from current direct-to-patient prices. Its sales of Zepbound have tripled this year to over $9 billion.
Nov 06, 2025 · 6 articles
Tech
Impact: Eli Lilly and Company produces donanemab (Kisunla), one of the anti-amyloid drugs whose effectiveness was questioned by the Cochrane review, potentially impacting its sales and stock price.
Apr 16, 2026 · 6 articles
Business
Impact: Eli Lilly and Company is a leading pharmaceutical company with strong balance sheets, enabling it to be a major acquirer in the current M&A wave. It is also facing patent expirations on some of its blockbuster drugs.
May 01, 2026 · 6 articles
Business
Eli Lilly and Company has expanded its collaboration with Camurus by exercising an option to include amylin receptor agonists in their existing license agreement. This decision grants Eli Lilly and Company exclusive global rights to…
Impact: Eli Lilly and Company expanded its exclusive global rights to Camurus' Fluid Crystal technology, allowing it to develop and commercialize long-acting cardiometabolic drugs for an additional compound class, which could lead to new revenue streams.
Jun 01, 2026 · 10 articles
Tech
Scientists have reported promising results from a groundbreaking gene-editing therapy, VERVE-102, developed by Verve PCSK9-inhibitor gene therapy>>>, a subsidiary of Eli Lilly and Company>>>. This therapy aims to permanently reduce 'bad' cholesterol (LDL cholesterol) after…
Impact: As the parent company of Verve PCSK9-inhibitor gene therapy>>>, Eli Lilly and Company>>> is a key developer of VERVE-102, a gene-editing therapy that has shown promising results in lowering cholesterol. This breakthrough could significantly impact its future market position in cardiovascular medicine.
May 26, 2026 · 12 articles
Tech
New research presented at the 2026 American Society of Clinical Oncology>>> Annual Meeting indicates that GLP-1 medications, widely used for weight loss and diabetes, may significantly reduce the risk of developing various cancers, including breast…
Impact: Eli Lilly and Company>>> produces GLP-1 drugs like Zepbound, Mounjaro, and Trulicity, which are showing potential benefits in cancer prevention and treatment.
Jun 02, 2026 · 37 articles
Business
Impact: Eli Lilly and Company is a key competitor to Novo Nordisk in the obesity drug market, with its drug Zepbound surpassing Wegovy in US prescriptions, contributing to Novo Nordisk's market challenges.
May 16, 2025 · 7 articles
Business
Impact: Eli Lilly and Company is a major competitor to Novo Nordisk in the weight-loss and diabetes drug market, with its drug Zepbound gaining market share against Novo Nordisk's Wegovy.
Sep 10, 2025 · 6 articles
Business
Impact: Eli Lilly and Company's drug Tirzepatide has been a strong competitor to Semaglutide in India, prompting Novo Nordisk to cut prices. Eli Lilly and Company has gained significant market share.
Nov 11, 2025 · 6 articles
Business
Impact: Eli Lilly and Company faces increased competition with Novo Nordisk's Wegovy pill launch, potentially impacting its market dominance in weight-loss drugs. Its shares fell following the announcement.
Jan 05, 2026 · 7 articles
Tech
Impact: Eli Lilly and Company produces Tirzepatide and Tirzepatide, which are GLP-1 agonist drugs. The study's findings on rapid weight regain after stopping medication could affect the perceived long-term efficacy and market demand for their products.
Jan 08, 2026 · 6 articles
Tech
Impact: Eli Lilly and Company collaborated on a new study that found a 71% higher risk of cardiovascular events or death in people with obstructive sleep apnea, especially those with obesity. This research could influence the development of new treatments and diagnostics, potentially benefiting Eli Lilly and Company's market position in related therapeutic areas.
Apr 03, 2026 · 6 articles
Domestic
France has announced that it will begin reimbursing the cost of weight-loss drugs, specifically Novo Nordisk's Semaglutide and Eli Lilly and Company's Tirzepatide, for severely obese patients starting mid-June. This makes France the first European…
Impact: Eli Lilly and Company's drug, Tirzepatide, is also included in France's reimbursement plan, which will expand its market reach within the European Union.
May 28, 2026 · 6 articles
Regulatory
Parker Waichman LLP has filed multiple lawsuits against pharmaceutical giants Novo Nordisk and Eli Lilly and Company, alleging that their popular GLP-1 receptor agonist medications, Semaglutide, Semaglutide, Tirzepatide, and Tirzepatide, caused Non-Arteritic Anterior Ischemic Optic…
Impact: Eli Lilly and Company is a pharmaceutical company also facing lawsuits for its GLP-1 medications, Tirzepatide and Tirzepatide, which are alleged to have caused NAION. The company is accused of failing to warn consumers about these risks.
May 22, 2026 · 7 articles
Domestic
Impact: Eli Lilly and Company rose after the United States — Food and Drug Administration approved its new weight loss pill, Foundayo.
Apr 01, 2026 · 14 articles
Business
Convatec and the Eli Lilly and Company have jointly committed approximately $5 million to Partners In Health, an international nonprofit global health organization. This funding aims to accelerate the integration of non-communicable disease (NCD) and…
Impact: Eli Lilly and Company supports the Eli Lilly and Company, which committed approximately $5 million to Partners In Health. This contributes to its philanthropic efforts in global health.
Jun 09, 2026 · 6 articles
Business
Global stock markets experienced a significant rally, primarily fueled by a stronger-than-expected quarterly report from Nvidia, which saw its profit and revenue surge due to high demand for its AI chips. This boosted technology shares…
Impact: Eli Lilly and Company>>> advanced after positive trial results for its next-generation obesity drug, retatrutide, which showed benefits beyond weight loss.
May 20, 2026 · 66 articles
International
The United States and Iran are engaged in complex negotiations to extend a fragile ceasefire and work towards a comprehensive peace deal, following a three-month conflict that has impacted global energy markets. A preliminary agreement…
Impact: Eli Lilly and Company>>> advanced after CVS Health>>> announced it would restore coverage for its weight-loss injection, Zepbound, and add its new obesity pill Foundayo.
May 18, 2026 · 309 articles
International
The United States and Iran have reached a tentative agreement to extend their three-month-old ceasefire by 60 days and initiate a new round of talks on Iran's nuclear program. This comes amidst wavering truce conditions,…
Impact: Eli Lilly and Company>>> advanced after CVS Health>>> announced it would restore coverage for its weight-loss injection, Zepbound, and add its new obesity pill Foundayo.
May 27, 2026 · 101 articles
Domestic
Impact: Eli Lilly and Company, among other pharmaceutical companies, had previously announced investments in U.S. production due to the threat of tariffs, but the new, higher tariffs introduce further uncertainty.
Sep 26, 2025 · 7 articles
Business
Impact: Eli Lilly and Company is a competitor in the Indian weight-loss drug market with its product Mounjaro, which has seen greater uptake than Novo Nordisk's Wegovy.
Nov 10, 2025 · 6 articles
Business
Phemex, a crypto exchange, has expanded its TradFi ecosystem to include 73 active assets, integrating high-performance contracts from healthcare leaders like Eli Lilly and Company and Novo Nordisk, and semiconductor powerhouses such as Samsung Electronics…
Impact: Eli Lilly and Company is one of the healthcare leaders whose contracts were added to Phemex's TradFi ecosystem, making its assets available for 24/7 trading to Phemex users.
Jun 03, 2026 · 6 articles
Domestic
President Donald Trump>>> announced the second expansion of his administration's direct-to-consumer drug platform, TrumpRx, adding 160 prescription medications to bring the total to over 800. This initiative aims to provide discounted prices for four out…
Impact: Eli Lilly and Company>>> is one of the pharmaceutical companies participating in the TrumpRx program, agreeing to reduce prices on certain medications.
Jun 06, 2026 · 8 articles
Business
MiNK Therapeutics, a genomic medicine company, has announced it is exploring strategic alternatives to maximize value for its stakeholders. The company has retained Raymond James Financial as its financial advisor to assist in evaluating options…
Impact: Eli Lilly and Company has licensed MiNK Therapeutics' STAC-BBB platform for neurological targets, indicating a past business relationship that could be affected by Sangamo's strategic review.
Jun 08, 2026 · 7 articles
Regulatory
Impact: Eli Lilly and Company is mentioned as another drugmaker that has recently announced sizeable investments in the United States.
Apr 22, 2025 · 6 articles
Business
Impact: Eli Lilly and Company is poised to bring a daily weight-loss pill to the UK, contributing to the competitive landscape that has challenged WW International.
May 07, 2025 · 6 articles
Domestic
Impact: Eli Lilly and Company saw gains that helped offset drops in other sectors, contributing to the overall positive market performance.
Dec 11, 2025 · 7 articles
Business
Impact: Gavin Barnard previously held senior leadership roles at Eli Lilly and Company, contributing to his extensive biopharma experience.
Apr 16, 2026 · 6 articles
+ 24 more events
View on Dashboard
100
Eli Lilly and Company agreed to buy ĆurevoEli Lilly acquires three...
100
Eli Lilly and Company agreed to buy LimmaTech BiologicsEli Lilly acquires three...
100
Eli Lilly and Company agreed to buy Vaccine CompanyEli Lilly acquires three...
100
Eli Lilly and Company exercised option CamurusEli Lilly Expands Camurus...
100
Hanmi Pharm entered into agreement Eli Lilly and CompanyHanmi licenses...
95
Eli Lilly and Company expanded rights CamurusEli Lilly Expands Camurus...
90
Eli Lilly and Company obtained exclusive rights Hanmi PharmHanmi licenses...
90
Eli Lilly and Company produced GLP-1 drugsGLP-1 Drugs Reduce Cancer Risk
90
Eli Lilly and Company committed funds Partners In HealthConvatec, Lilly Foundation...
90
Parker Waichman LLP filed lawsuits Eli Lilly and CompanyParker Waichman Sues Novo...
85
Eli Lilly and Company produced drugsParker Waichman Sues Novo...
80
Eli Lilly and Company made initial payment CamurusEli Lilly Expands Camurus...
80
Hanmi Pharm received upfront payment Eli Lilly and CompanyHanmi licenses...
75
Eli Lilly and Company plans Phase 2 studyVERVE-102 Gene Edit Lowers...
40
Eli Lilly and Company released trial resultsNvidia Earnings, Samsung...
40
CVS Health restore coverage Eli Lilly and CompanyUS-Iran Ceasefire...
+ 22 more relationships
View on Dashboard
NEWSDESK
Track Eli Lilly and Company live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard